ARKG
ARK Innovation ETF
Is ARKG Halal?
Genomics and biotechnology ETF with passing known asset ratios but incomplete look-through activity and purification analysis.
What You Should Know
ARKG's January 31, 2026 semi-annual shareholder report reports approximately USD 1,280.199 million of total assets, no debt, USD 2.676 million of money-market holdings, USD 10.656 million of receivables and 98.8% healthcare exposure. Known debt/assets is 0.00%, liquidity/assets is 0.21% and receivables-plus-cash/assets is 0.83%; no universal prohibited-income numerator is disclosed for the underlying issuers. Medical research is generally permissible, but gene editing, reproductive applications, clinical materials and issuer-level financial activity require review.
⚠️ Concerns
- •Underlying biotechnology and gene-editing activities require product-level review
- •Clinical materials, reproductive applications and animal research raise school-specific questions
- •Underlying issuers are not all screened under one Sharia methodology
- •ETF structure and securities-lending income require continuing review
Current quantitative Sharia screen
Based on N-CSRS figures for the period ended 2026-01-31; calculated 2026-07-15.
0 / 1,280.199
2.676 / 1,280.199
10.656 / 1,280.199
- Financial
- Incomplete
- Overall
- Incomplete
Debt/assets is 0.00%, liquidity/assets is 0.21% and receivables-plus-cash/assets is 0.83%; no fund-level income numerator is available for the FTSE income threshold and the underlying activity screen remains incomplete.
- Financial
- Pass
- Overall
- Incomplete
Known debt, liquidity and receivables-plus-cash ratios are below the examined MSCI limits; underlying issuer activity is not classified by a universal prohibited-revenue numerator.
- Financial
- Pass
- Overall
- Incomplete
Known debt/assets and liquidity/assets are below the examined Malaysia limits; this pass-through portfolio remains qualitatively incomplete.
- Financial
- Not calculated
- Overall
- Incomplete
A licensed historical market-cap series and fund-level prohibited-income convention are not stored.
Business-activity disclosure
ARKG invests primarily in companies relevant to the genomics revolution, with the January 2026 report showing 98.8% healthcare exposure. Medical research and biotechnology can be permissible, while gene editing, clinical materials, reproductive applications and each underlying issuer's financial activity require school-specific review.
Limitation: The fund reports holdings and sector weights but does not provide a universal prohibited-revenue numerator for every underlying issuer.
Purification
ARKG does not disclose a scholar-approved fund-level purification percentage or universal prohibited-income allocation.
Inputs, assumptions and primary sources
- Amounts are USD millions from ARKG's January 31, 2026 semi-annual shareholder report; total assets reconcile investments of USD 1,269.543 million and disclosed receivables of USD 10.656 million.
- The fund reports no debt and no cash balance; USD 2.676 million of money-market-fund holdings are treated as identifiable interest-bearing securities.
- Receivables include dividends and interest, capital shares sold, investment securities sold and securities-lending income receivables.
- The report does not provide a school-neutral operating-revenue denominator or complete prohibited-income allocation for the underlying holdings, so totalRevenue and nonCompliantIncome remain unavailable for purification.
- ARKG is an actively managed genomics ETF; underlying biotechnology, diagnostics, gene-editing and issuer-level financial activity require look-through scholarly review.
This is a reproducible financial screen, not a fatwa. A failed total-assets screen can coexist with a pass under a market-cap methodology. ZakatInvest keeps the qualitative assessment separate so numerical thresholds do not erase material context.
Similar ETFs
Want to screen more assets?
Use our interactive Halal Checker to screen any stock, ETF, or crypto instantly.
Go to Halal Checker →